For: | Tasneem M, Mannix C, Wong A, Zhang J, Rangan G. Is serum copeptin a modifiable biomarker in autosomal dominant polycystic kidney disease? World J Nephrol 2018; 7(2): 51-57 [PMID: 29527508 DOI: 10.5527/wjn.v7.i2.51] |
---|---|
URL: | https://www.wjgnet.com/2220-6124/full/v7/i2/51.htm |
Number | Citing Articles |
1 |
Stéphanie De Rechter, Bert Bammens, Franz Schaefer, Max C Liebau, Djalila Mekahli. Unmet needs and challenges for follow-up and treatment of autosomal dominant polycystic kidney disease: the paediatric perspective. Clinical Kidney Journal 2018; 11(suppl_1): i14 doi: 10.1093/ckj/sfy088
|
2 |
Alessandro Maria Berton, Emanuele Varaldo, Nunzia Prencipe, Francesca Rumbolo, Fabio Settanni, Andrea Benso, Silvia Grottoli. Attuali applicazioni della determinazione dei livelli plasmatici di copeptina in contesti non-endocrinologici. L'Endocrinologo 2022; 23(6): 592 doi: 10.1007/s40619-022-01180-8
|
3 |
Maksymilian Kłosowicz, Dawid Leksa, Dorota Bartusik-Aebisher, Angelika Myśliwiec, Klaudia Dynarowicz, David Aebisher. Biomarkers That Seem to Have the Greatest Impact on Promoting the Formation of Atherosclerotic Plaque in Current Scientific Research. Current Issues in Molecular Biology 2024; 46(9): 9503 doi: 10.3390/cimb46090564
|
4 |
Kuldeep Dhama, Shyma K. Latheef, Maryam Dadar, Hari Abdul Samad, Ashok Munjal, Rekha Khandia, Kumaragurubaran Karthik, Ruchi Tiwari, Mohd. Iqbal Yatoo, Prakash Bhatt, Sandip Chakraborty, Karam Pal Singh, Hafiz M. N. Iqbal, Wanpen Chaicumpa, Sunil Kumar Joshi. Biomarkers in Stress Related Diseases/Disorders: Diagnostic, Prognostic, and Therapeutic Values. Frontiers in Molecular Biosciences 2019; 6 doi: 10.3389/fmolb.2019.00091
|
5 |
Thomas Roe, Jessie Welbourne, Nikitas Nikitas. Endocrine dysregulation in aneurysmal subarachnoid haemorrhage. British Journal of Neurosurgery 2022; 36(3): 358 doi: 10.1080/02688697.2022.2039378
|